Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Presentation for Financial Results for the Fiscal Year Ending January 31, 2025
Notice Concerning Differences between Consolidated Earnings Forecast and Actual Results for the Fiscal Year Ending January 31, 2025
Notice Concerning Recording of Non-operating Income, Non-operating Expenses, Extraordinary Gains, and Deferred Income Taxes
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
Consolidated Financial Results for the Fiscal Year Ended January 31, 2025[Japanese GAAP]
Publication of Results of Cell Implantation Location Analysis from STEMTRA Trial in Neurotrauma Reports
The Results of the Second Commercial Production Run of AKUUGO(R)
[Delayed] Conclusion of Contract Manufacturing Agreement with JCR Pharma for Trial Production of AKUUGO
Determination of Terms and Conditions of Stock Options(Share Acquisition Rights)
Revision of Consolidated Earnings Forecast for the Fiscal Year Ending January 2025
Announcement on Granting Stock Options (Share Acquisition Rights)
Publication of an Article in Molecular Therapy of SB623
Announcement on Acquisition and Cancellation of Stock Options (Share Acquisition Rights)
Notice Concerning Recording of Non-operating Income, Extraordinary Gains, and Deferred Income Taxes
Consolidated Financial Results for the Nine Months Ended October 31, 2024 [Japanese GAAP]
The Yield Results of the Second Commercial Production Run for AKUUGO(R)
The Results of the First Commercial Production Run of AKUUGO(R)
Notice Concerning the Grant of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the United States
Notice Concerning Today’s Meeting of the Pharmaceutical Affairs Council
Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2025